RevBio
Lowell
About RevBio
RevBio is commercializing an injectable, self-setting, osteoconductive bone adhesive biomaterial that can bond bone to bone and bone to metal in a wet field environment. The company's showcase product, Tetranite, is being reviewed by the FDA for a growing body of applications including oral, craniofacial, orthopedic, and neurosurgical indications. Over time, this synthetic adhesive biodegrades and is replaced by new bone. This unique material will reduce the duration and complexity of medical procedures, allow for more minimally invasive surgeries, and will improve patient outcomes by reducing recovery time and the overall cost of care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $42.1M
- Last round: Grant (Oct 2025)
- Website: revbio.com
- Phone: 617-947-6246
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/revbio-72243 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.